Search Within

Charles Ryan

Formats
  1. Meeting Abstract (8)
  2. Journal Article (7)
  3. Editorial (1)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Biostatistics Service (6)
  5. Epidemiology and Biostatistics (6)
  6. Department of Pathology and Laboratory Medicine (4)

More Groups

People
  1. Howard Scher (7)
  2. Alexander Smith (4)
  3. Jaya Satagopan (4)
  4. Michael Morris (4)
  5. Peter Scardino (4)
  6. Priti Lal (4)

More People

Years
  1. 2025 (7)
  2. 2014 (1)
  3. 2007 (1)
  4. 2006 (1)
  5. 2004 (2)
  6. 2003 (2)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Urology (2)
  3. American Journal of Pathology (1)
  4. Cancers (1)
  5. Drugs & Aging (1)
  6. Journal of Urology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Elsevier Science, Inc. (4)
  3. Adis International Ltd (1)
  4. Harborside Press (1)
  5. MDPI (1)
  6. Nature Publishing Group (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The influence of the germline HSD3B1 adrenal-permissive allele (c.1100 C) on the somatic alteration landscape, the transcriptome, and immune cell infiltration in prostate cancer
    Journal Article

    Kellen, S.; Makovec, A.; Miller, C. D.; Nazari, S. S.; Elliott, A.; Deacon, A.; John, E.; Vobugari, N.; Agarwal, N.; McKay, R. R.; more...
    Cancers (2025)

    Fulltext@MSK | Save
  • Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial
    Meeting Abstract

    Ryan, C. J.; Kim, H.; Morris, M. J.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Sharifi, N.; Halabi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate
    Meeting Abstract

    Morgans, A. K.; Ma, Y.; Jackson, J. C.; Ryan, C. J.; Moses, K. A.; Barata, P. C.; Dorff, T. B.; Kocherginsky, M.; Vanderweele, D. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance)
    Meeting Abstract

    Sharifi, N.; Kim, H.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Morris, M. J.; Halabi, S.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Ryan, C. J.; Lacuna, K. P.; Yoo, L.; Szmukier, Z.; Boldt-Houle, D. M.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Uncharted territory: Investigating long-term quality of survival after a prostate cancer diagnosis
    Editorial

    Morgans, A. K.; Ryan, C. J.
    Journal of the National Comprehensive Cancer Network (2025)

    Fulltext@MSK | Save
  • Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials
    Meeting Abstract

    Fizazi, K.; Flaig, T. W.; Ohlmann, C. H.; Scher, H. I.; de Bono, J. S.; Rathkopf, D. E.; Ryan, C. J.; Kheoh, T. S.; Li, J. H.; Todd, M. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression
    Journal Article

    Ryan, C. J.; Smith, A.; Lal, P.; Satagopan, J.; Reuter, V.; Scardino, P.; Gerald, W.; Scher, H. I.
    Urology (2006)

    Fulltext@MSK | Save